JP5196701B2 - クロモリンナトリウムの経口投与用製剤 - Google Patents

クロモリンナトリウムの経口投与用製剤 Download PDF

Info

Publication number
JP5196701B2
JP5196701B2 JP2003546836A JP2003546836A JP5196701B2 JP 5196701 B2 JP5196701 B2 JP 5196701B2 JP 2003546836 A JP2003546836 A JP 2003546836A JP 2003546836 A JP2003546836 A JP 2003546836A JP 5196701 B2 JP5196701 B2 JP 5196701B2
Authority
JP
Japan
Prior art keywords
cromolyn
delivery agent
sodium
cromolyn sodium
snac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003546836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510535A5 (enExample
JP2005510535A (ja
Inventor
リチャット アッバス
エウド アービット
マイケル ゴールドバーグ
ヴィヴィアン ウォン
ドナルド ジェイ サラッビ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Publication of JP2005510535A publication Critical patent/JP2005510535A/ja
Publication of JP2005510535A5 publication Critical patent/JP2005510535A5/ja
Application granted granted Critical
Publication of JP5196701B2 publication Critical patent/JP5196701B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2003546836A 2001-11-29 2002-11-29 クロモリンナトリウムの経口投与用製剤 Expired - Fee Related JP5196701B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33439501P 2001-11-29 2001-11-29
US60/334,395 2001-11-29
US38491602P 2002-05-24 2002-05-24
US60/384,916 2002-05-24
PCT/US2002/038247 WO2003045331A2 (en) 2001-11-29 2002-11-29 Formulations for oral administration of cromolyn sodium

Publications (3)

Publication Number Publication Date
JP2005510535A JP2005510535A (ja) 2005-04-21
JP2005510535A5 JP2005510535A5 (enExample) 2006-02-02
JP5196701B2 true JP5196701B2 (ja) 2013-05-15

Family

ID=26989179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546836A Expired - Fee Related JP5196701B2 (ja) 2001-11-29 2002-11-29 クロモリンナトリウムの経口投与用製剤

Country Status (6)

Country Link
US (2) US20040259952A1 (enExample)
EP (1) EP1461031B1 (enExample)
JP (1) JP5196701B2 (enExample)
AU (1) AU2002352974A1 (enExample)
CA (1) CA2466863A1 (enExample)
WO (1) WO2003045331A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
CA2563335A1 (en) 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
ES2393324T3 (es) * 2004-05-14 2012-12-20 Emisphere Technologies, Inc. Compuestos y composiciones para administrar principios activos
BRPI0510820A (pt) 2004-05-19 2007-11-27 Emisphere Tech Inc composição farmacêutica, forma unitária de dosagem e seus usos
BRPI0510906A (pt) * 2004-05-19 2007-11-06 Emisphere Tech Inc composição farmacêutica tópica, composição para administração tópica e seu uso
MX2007008082A (es) 2004-12-29 2007-09-05 Emisphere Tech Inc Formulaciones farmaceuticas de sales de galio.
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP4558045B2 (ja) * 2005-11-01 2010-10-06 株式会社リバース・プロテオミクス研究所 アレルギー疾患の治療に有用な化合物をスクリーニングする方法
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
WO2008003050A2 (en) 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
WO2009045291A2 (en) * 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP3567033A1 (en) * 2009-01-29 2019-11-13 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US8843456B2 (en) 2011-12-06 2014-09-23 International Business Machines Corporation Database table compression
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US20160082075A1 (en) * 2013-03-27 2016-03-24 Scpharmaceuticals Inc. Combination Therapy for Subcutaneous Administration of Glycopeptide Antibiotics
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2016535793A (ja) * 2013-11-11 2016-11-17 ジヴ エム．ディー． ハリシュ 口腔アレルギー症候群の予防および治療のための製剤および方法
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
JP2017505348A (ja) 2014-02-10 2017-02-16 パタラ ファーマ リミテッド ライアビリティ カンパニー 肺疾患治療のための肥満細胞安定剤
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
CN109069475B (zh) * 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
MX2019001850A (es) 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
JP2019528320A (ja) * 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
CN111629719A (zh) * 2017-12-04 2020-09-04 通用医疗公司 色甘酸组合物及其方法
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
US11986492B2 (en) * 2022-09-21 2024-05-21 Ashley Wolchina Allison Oral supplement for preventing colic in horses
CN116509836A (zh) * 2023-03-23 2023-08-01 中山万汉制药有限公司 色甘酸钠－季铵盐复合物及其制备方法与用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281380A (ja) * 1985-10-04 1987-04-14 Kyoto Yakuhin Kogyo Kk クロモグリク酸誘導体、その製造法および抗アレルギ−剤
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
JPH06281380A (ja) 1993-03-26 1994-10-07 Hisaka Works Ltd プレート式熱交換器用ガスケット
IL109403A0 (en) * 1993-04-22 1994-07-31 Emisphere Tech Inc Oral drug delivery compositions and methods
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JP3124041B2 (ja) * 1996-08-30 2001-01-15 京都薬品工業株式会社 アレルギー性皮膚炎治療剤
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5888529A (en) * 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5952353A (en) * 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions
AU751612B2 (en) * 1998-07-27 2002-08-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL140930A0 (en) * 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
EP1163209A4 (en) * 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
MXPA02004092A (es) * 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
EP1237872B1 (en) * 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2292902C (en) * 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6225356B1 (en) * 2000-01-20 2001-05-01 Jones, Iii Tudor Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea
WO2001060413A2 (en) * 2000-02-15 2001-08-23 Board Of Trustees Of The University Of Arkansas Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases
NZ523017A (en) * 2000-06-29 2004-10-29 Emisphere Tech Inc Compounds and compositions for delivering active agents and preparation method thereof
JP5089845B2 (ja) * 2000-09-06 2012-12-05 エミスフェアー・テクノロジーズ・インク シアノフェノキシカルボン酸化合物および活性薬剤送達用組成物

Also Published As

Publication number Publication date
WO2003045331A3 (en) 2003-08-14
JP2005510535A (ja) 2005-04-21
EP1461031B1 (en) 2016-06-29
US20080194676A1 (en) 2008-08-14
US8513300B2 (en) 2013-08-20
EP1461031A2 (en) 2004-09-29
AU2002352974A8 (en) 2003-06-10
CA2466863A1 (en) 2003-06-05
US20040259952A1 (en) 2004-12-23
EP1461031A4 (en) 2011-06-22
WO2003045331A2 (en) 2003-06-05
AU2002352974A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
US8513300B2 (en) Formulations for oral administration of cromolyn sodium
KR100296954B1 (ko) 신규의항알러지항염증조성물
US8426368B2 (en) Method of ameliorating oxidative stress and supplementing the diet
EP3388417A1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
WO2022104022A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
US11213484B2 (en) Dipivefrin orally disintegrating tablet formulations
TW201438713A (zh) 治療帕金森疾病的新穎高穿透性藥物和醫藥組合物
CA2827336A1 (en) Flumazenil complexes, compositions comprising same and uses thereof
EA010295B1 (ru) Соединения амфетамина с пониженной способностью вызывать злоупотребление ими
US11654198B2 (en) Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia
EP3952851B1 (en) Compounds and uses thereof for treating inflammatory disorders
KR20210002573A (ko) 간 질환에 호중구 엘라스타제 저해제의 사용
WO2021185265A1 (zh) 口服药物组合物
US10493122B2 (en) Sublingual delivery of glatiramer acetate
US11590232B2 (en) Bioconjugates of neuropeptides derivatives
JP2006515622A (ja) 規制物質の乱用を防止するための炭水化物共役体
WO2023108074A1 (en) Novel salvinorin compositions
WO2010038240A9 (en) Pharmaceutical composition comprising nimesulide and levocetirizine
JP7607939B2 (ja) 喘息を治療するための方法
JPWO2004087148A1 (ja) 肺疾患の治療および／または予防剤
WO2025084921A1 (es) Desarrollo de formulaciones para el manejo y tratamiento antiviral, inmunomodulador y antiinflamatorio de la infección por el nuevo sars-cov2 y la enfermedad desarrollada el covid-19 y sus variantes, formulada a partir de la sal del ácido glicirricínico y sus derivados de su estructura química
CN118591395A (zh) 用于治疗新生儿病患的催产素缀合物
JPH10259124A (ja) 咽頭疾患用組成物
JPWO2004112791A1 (ja) 肺疾患の治療および／または予防剤
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051128

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20051128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100608

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130205

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160215

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees